Exhaled nitric oxide in childhood allergic asthma management: A randomised controlled trial
| Autor: | Kristine Desager, Eva J. Peirsman, Kate Sauer, Marc Raes, Luc Pattyn, Thierry J. Carvelli, Françoise Vermeulen, Laurence S. Hanssens, Pierre Y. Hage |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Asthma exacerbations business.industry medicine.drug_class Leukotriene receptor Antagonist Allergic asthma respiratory tract diseases law.invention Randomized controlled trial law Interquartile range Anesthesia Internal medicine Pediatrics Perinatology and Child Health Exhaled nitric oxide Medicine Corticosteroid business |
| Zdroj: | Pediatric Pulmonology. 49:624-631 |
| ISSN: | 8755-6863 |
| Popis: | exacerbations were registered in the FeNO group. 24% of the children in the FeNO group experienced one or more exacerbations per year, compared with 48% in the clinical group (P ¼0.017). The proportion of symptom-free days did not differ between groups. In the FeNO group, more months of leukotriene receptor antagonist use (median (interquartile range)) were observed: 12 (9–12) months, compared with 9 (3–12) months in the clinical group (P ¼0.019). Next, the evolution of inhaled corticosteroid doses between visits 1 and 5 (median change (interquartile range)) showed a significant increase of þ100m g( 0,þ400) in the FeNO group and a change of 0m g( � 200, þ80) in the clinical group (P ¼0.016). Conclusions: FeNO measurements in childhood asthma management did not improve the proportion of symptomfree days, but did result in fewer asthma exacerbations associated with an increased leukotriene receptor antagonist use and an augmentation of the inhaled corticosteroid doses. Pediatr |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text